The deal is a non-exclusive agreement and the companies were selected through an international bidding process. The arrangement includes the transfer of technology dealing with the manufacture, testing, packaging, storage and handling of the drug's active ingredient. The drug is a second line antiretroviral for patients who have developed a resistance to more common drugs. Peter Dolan, the chief executive of BMS, said the company has taken a broad-based approach to addressing the Aids crisis, which included providing Aids medicines at no-profit prices.
South African and Indian firms win aids drug license
Aspen Pharmacare, South Africa, and Emcure Pharmaceuticals, India, have won a royalty-free licence agreement for the generic of Bristol-Myers Squibb's (BMS) antiretroviral drug Atazanavir, which earned BMS $696 million in sales in the US last year. Atazanavir is known as Reyataz in the US.
May 31, 2007
Recommended
Recommended
Machinery Basics
Sponsor Content
Annual Outlook Report: Automation & Robotics
What's in store for CPGs in 2025 and beyond? Packaging World editors explore the survey responses from 118 brand owners, CPG, and FMCG Packaging World readers for its new Annual Outlook Report.
Download
List: Digitalization Companies From PACK EXPO
Looking for CPG-focused digital transformation solutions? Download our editor-curated list from PACK EXPO featuring top companies offering warehouse management, ERP, digital twin, and MES software with supply chain visibility and analytics capabilities—all tailored specifically for CPG operations.
Download Now
